Feb 26, 2026 07:00AM
Jan 13, 2026 07:01AM
Jan 13, 2026 07:00AM
Dec 11, 2025 07:02AM
Dec 11, 2025 07:00AM
Nov 16, 2025 03:00PM
Oct 31, 2024 07:30AM Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Oct 9, 2024 07:01AM
Oct 9, 2024 07:00AM
Jun 20, 2024 08:45AM
Jan 17, 2024 08:00AM
Nov 2, 2023 09:00AM
Nov 2, 2023 07:00AM
Oct 27, 2023 07:00AM Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Pay
Sep 18, 2023 07:01AM
Sep 18, 2023 07:00AM
Aug 3, 2023 07:00AM
Jun 22, 2023 08:30AM
May 4, 2023 07:00AM
Feb 23, 2023 07:00AM
Feb 23, 2023 07:00AM Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Jan 10, 2023 07:07AM
Jan 10, 2023 07:00AM
Jan 10, 2023 07:00AM
Dec 14, 2022 07:24AM
Dec 14, 2022 07:00AM
Dec 14, 2022 07:00AM
Nov 3, 2022 07:05AM Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
Nov 3, 2022 07:05AM
Sep 15, 2022 07:30AM
Sep 15, 2022 07:30AM
Aug 11, 2022 10:01AM
Aug 9, 2022 07:00AM
Jun 15, 2022 07:01AM
Jun 15, 2022 07:00AM Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413
Jun 1, 2022 08:43AM
Jun 1, 2022 08:42AM
May 3, 2022 07:00AM
May 3, 2022 07:00AM
Feb 24, 2022 07:00AM
Feb 24, 2022 07:00AM
Nov 30, 2021 08:02AM Kymera Therapeutics (KYMR) Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Nov 30, 2021 08:00AM
Nov 30, 2021 08:00AM
Nov 10, 2021 07:00AM
Nov 10, 2021 07:00AM
Aug 6, 2021 07:00AM
Aug 6, 2021 07:00AM
Jul 12, 2021 08:00AM Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum
Jul 12, 2021 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All